How do regulatory bodies (e.g., MHRA, FDA) classify cell-free extracellular vesicle products versus human cell and tissue products
Regulation Traceability Consent Women’s Health Clinic FAQ How do regulatory bodies (e.g., MHRA, FDA) classify cell-free extracellular vesicle products versus human cell and tissue products Regulatory…
What is the biological risk of exosome signalling upregulating angiogenesis in undetected pre-cancerous lesions (e.g., VIN or CIN)
Cancer safety Screening Caution Women’s Health Clinic FAQ What is the biological risk of exosome signalling upregulating angiogenesis in undetected pre-cancerous lesions (e.g., VIN or CIN)…
How do clinicians screen for active pelvic or vulvar malignancies prior to administering exosome biostimulation therapy
Cancer safety Screening Caution Women’s Health Clinic FAQ How do clinicians screen for active pelvic or vulvar malignancies prior to administering exosome biostimulation therapy Exosome safety…
What is the oncological safety profile of MSC exosomes in patients with a history of hormone-receptor-positive breast cancer
Cancer safety Screening Caution Women’s Health Clinic FAQ What is the oncological safety profile of MSC exosomes in patients with a history of hormone-receptor-positive breast cancer…
Why are cell-free exosomes immunologically safer regarding teratoma formation and immune rejection compared to live stem cell therapies
Immune safety Allergy Escalation Women’s Health Clinic FAQ Why are cell-free exosomes immunologically safer regarding teratoma formation and immune rejection compared to live stem cell therapies…
How do ethical clinics present transparent consent regarding the origin, processing, and clinical evidence base for exosome therapies
Regulation Traceability Consent Women’s Health Clinic FAQ How do ethical clinics present transparent consent regarding the origin, processing, and clinical evidence base for exosome therapies Regulatory…
What precautions are required to prevent exosome degradation during clinical handling, agitation, or syringe transfer
Handling Stability Governance Women’s Health Clinic FAQ What precautions are required to prevent exosome degradation during clinical handling, agitation, or syringe transfer Handling and reconstitution topics…
How does the presence of an active bacterial or fungal vaginal infection affect exosome signalling and safety protocols
Infection Mucosa Deferral Women’s Health Clinic FAQ How does the presence of an active bacterial or fungal vaginal infection affect exosome signalling and safety protocols Active…
What is the safety profile of intimate exosome injections in patients with active autoimmune diseases like systemic lupus erythematosus
Immune risk Specialist review Suitability Women’s Health Clinic FAQ What is the safety profile of intimate exosome injections in patients with active autoimmune diseases like systemic…
How do clinicians manage patient inquiries regarding off-label regenerative claims vs. established clinical trial evidence for exosomes
Regulation Traceability Consent Women’s Health Clinic FAQ How do clinicians manage patient inquiries regarding off-label regenerative claims vs. established clinical trial evidence for exosomes Regulatory and…
Still not sure where to start?
Browse the wider treatment pages or book a free consultation so we can help you find the most relevant next step.
